14q12q13.3 Deletion Diagnosed Using Chromosomal Microarray Analysis in an Infant Showing Seizures, Hypoplasia of the Corpus Callosum, and Developmental Delay
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
14q12q13.3 Deletion is a rare microdeletion syndrome associated with neurodevelopmental delay, failure to thrive, seizures, and abnormal brain development. Symptoms vary depending on the sites of gene deletion, and establishing the diagnosis is often difficult, as the condition cannot be detected with routine chromosome analysis. In this report, we present a patient with intrauterine growth retardation, microcephaly, muscle weakness, seizures, and hypoplasia of the corpus callosum who underwent diagnostic tests, including karyotyping in the neonatal period without leading to a specific diagnosis. The patient was confirmed with a serious developmental disorder, and a chromosomal microarray analysis was performed at 8 months of age, revealing a 14q12q13.3 deletion. In this case, the condition was diagnosed in early infancy, in contrast to previously reported cases, and the patient had diverse and severe symptoms. Establishing the diagnosis of 14q12q13.3 deletion syndrome allows better management of patient care and genetic counseling for the parents.
Abstract
14q12q13.3 Deletion is a rare microdeletion syndrome associated with neurodevelopmental delay, failure to thrive, seizures, and abnormal brain development. Symptoms vary depending on the sites of gene deletion, and establishing the diagnosis is often difficult, as the condition cannot be detected with routine chromosome analysis. In this report, we present a patient with intrauterine growth retardation, microcephaly, muscle weakness, seizures, and hypoplasia of the corpus callosum who underwent diagnostic tests, including karyotyping in the neonatal period without leading to a specific diagnosis. The patient was confirmed with a serious developmental disorder, and a chromosomal microarray analysis was performed at 8 months of age, revealing a 14q12q13.3 deletion. In this case, the condition was diagnosed in early infancy, in contrast to previously reported cases, and the patient had diverse and severe symptoms. Establishing the diagnosis of 14q12q13.3 deletion syndrome allows better management of patient care and genetic counseling for the parents.
참고문헌 (19)
- Ponzi E, "14q12q13.2 microdeletion syndrome: clinical characterization of a new patient, review of the literature, and further evidence of a candidate region for CNS anomalies", Mol Genet Genomic Med, 8, pp.e1289~ (2020)
- Santen GW, "Further delineation of the phenotype of chromosome 14q13 deletions: (positional) involvement of FOXG1 appears the main determinant of phenotype severity, with no evidence for a holoprosencephaly locus", J Med Genet, 49, pp.366~372 (2012)
- Resta N, "Chromosomal microarray (CMA) analysis in infants with congenital anomalies: when is it really helpful?", J Matern Fetal Neonatal Med, 25(Suppl 4), pp.124~126 (2012)
- Miller DT, "Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies", Am J Hum Genet, 86, pp.749~764 (2010)
- Feldkamp ML, "Etiology and clinical presentation of birth defects : population based study", BMJ, 357, pp.j2249~ (2017)
- Brent RL, "Addressing environmentally caused human birth defects", Pediatr Rev, 22, pp.153~165 (2001)
- Mai CT, "National population-based estimates for major birth defects, 2010-2014", Birth Defects Res, 111, pp.1420~1435 (2019)
- Hook EB, "Contribution of chromosome abnormalities to human morbidity and mortality", Cytogenet Cell Genet, 33, pp.101~106 (1982)
- Schinzel A, "Catalog of unbalanced chromosome aberrations in man" (2001), Walter de Gruyter
- Emy Dorfman L, "Microarraybased comparative genomic hybridization analysis in neonates with congenital anomalies: detection of chromosomal imbalances", J Pediatr(Rio J), 91, pp.59~67 (2015)
- Pickering DL, "Array-based comparative genomic hybridization analysis of 1176 consecutive clinical genetics investigations", Genet Med, 10, pp.262~266 (2008)
- Ellison JW, "Clinical utility of chromosomal microarray analysis", Pediatrics, 130, pp.e1085~e1095 (2012)
- Lalani SR, "Current genetic testing tools in neonatal medicine", Pediatr Neonatol, 58, pp.111~121 (2017)
- Florian C, "FOXG1-related disorders : from clinical description to molecular genetics", Mol Syndromol, 2, pp.153~163 (2012)
- Kortum F, "The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis", J Med Genet, 48, pp.396~406 (2011)
- Hardies K, "Recessive loss-of-function mutations in AP4S1 cause mild fever-sensitive seizures, developmental delay and spastic paraplegia through loss of AP-4 complex assembly", Hum Mol Genet, 24, pp.2218~2227 (2015)
- Gentile M, "14q13 distal microdeletion encompassing NKX2-1 and PAX9: patient report and refinement of the associated phenotype", Am J Med Genet A, 170, pp.1884~1888 (2016)
- McDonald DR, "Heterozygous N-terminal deletion of IkappaBalpha results in functional nuclear factor kappaB haploinsufficiency, ectodermal dysplasia, and immune deficiency", J Allergy Clin Immunol, 120, pp.900~907 (2007)
- Fonseca DJ, "A de novo 14q12q13.3 interstitial deletion in a patient affected by a severe neurodevelopmental disorder of unknown origin", Am J Med Genet A, 158A, pp.689~693 (2012)